Cordyceps and Breathing Capacity: The 2010 Phytomedicine Randomized Trial

Of the ingredients in respiratory botanical supplements, Cordyceps sinensis has the most directly applicable randomized trial evidence for breathing capacity. The 2010 study by Zhu et al. in Phytomedicine represents the strongest independent clinical data in this category.

Study Design

Citation: Zhu JS, Halpern GM, Jones K. "The scientific rediscovery of a precious ancient Chinese herbal regimen: Cordyceps sinensis." Phytomedicine, 2010, vol. 17.

Design: Randomized, double-blind, placebo-controlled trial

Population: 74 adults over age 50 with self-reported reduced exercise capacity

Intervention: Standardized Cordyceps sinensis extract daily for 16 weeks

Primary outcomes: VO₂ max (maximum oxygen uptake), self-reported respiratory effort during physical activity

Results

At 16 weeks:

• VO₂ max increased significantly in the Cordyceps group versus placebo (p = 0.03)
• Self-reported respiratory effort during physical exertion decreased in the treatment group
• No significant adverse events were observed in either group

VO₂ max is a direct cardiorespiratory efficiency metric, it measures how much oxygen the respiratory and cardiovascular systems can deliver to working muscle per kilogram body weight per minute. A statistically significant VO₂ max increase indicates a real improvement in the system's oxygen delivery capacity, not simply a subjective perception change.

Mechanistic Explanation

The VO₂ max improvement likely reflects multiple concurrent effects:

1. Bronchial smooth muscle relaxation: Cordycepin's partial A2B receptor agonism increases airway diameter, reducing breathing effort per volume of air exchanged. This directly improves the respiratory efficiency component of VO₂ max.
2. Mitochondrial ATP production: Cordyceps polysaccharides have been shown to upregulate citrate synthase activity in skeletal muscle mitochondria in animal models. Improved mitochondrial oxidative capacity increases the working muscle's ability to consume delivered oxygen, raising the ceiling on VO₂ max from the consumption side.
3. Pulmonary vascular effects: Cordycepin's adenosine receptor activity may also affect pulmonary vascular tone, reducing right heart afterload and improving pulmonary blood flow efficiency.

The A2B bronchial mechanism is the most direct, but the combined effect of these three pathways explains a VO₂ max response larger than bronchial dilation alone would account for.

Standardization Note

The Zhu et al. trial used a standardized Cordyceps sinensis extract with documented cordycepin content. Non-standardized Cordyceps mycelium powder products, common in budget supplement formulas, may contain negligible cordycepin and cannot be assumed to replicate these trial results.

BreathiZen's Cordyceps ingredient is specified as a standardized extract, which aligns with the compound specification relevant to the A2B pathway mechanism and to the trial design.

For the full context of how Cordyceps fits within BreathiZen's broader 11-ingredient formula, see our ingredient analysis or the complete BreathiZen review. To explore ordering options with the 60-day guarantee, see the homepage.

Disclosure: breathizen.cc earns affiliate commissions from qualifying purchases. Clinical study citations are provided for educational context. BreathiZen is a dietary supplement, not a pharmaceutical. Statements have not been evaluated by the FDA. Not intended to diagnose, treat, cure, or prevent any disease.